CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
6 research outputs found
A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer.
Author
Aminah Jatoi
Andrea Elisabeth Wahner Hendrickson
+6Â more
Dennis J. Slamon
Gottfried E. Konecny
Jill K. Burton
Jill Paroly
John A. Glaspy
Sean Christopher Dowdy
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.
Author
Andrea Elisabeth Wahner Hendrickson
Charles Erlichman
+11Â more
Donald W. Northfelt
Fleix Boakye-Agyeman
Guy G Poirier
Harry J. Long
Janet Lensing
Joel M. Reid
Karen S Flatten
Lynn C. Hartmann
Michael E. Menefee
Paul Haluska
Scott H. Kaufmann
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
Author
Andrea Elisabeth Wahner Hendrickson
Ann L. Oberg
+14Â more
Beverly Long
Ethan Heinzen
Evans Bradley
Gerardo Colon-Otero
Jamison VanBlaricom
Jill K. Burton
John Kelly Camoriano
Kimberly Kalli
Marc Becker
Matthew John Maurer
Nathan R. Foster
Paul Haluska
Saravut John Weroha
Xiaonan Hou
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
Author
Amit M. Oza
Andrea Elisabeth Wahner Hendrickson
+15Â more
Angeles Alvarez Secord
Bradley J. Monk
David S. Miller
Gini F. Fleming
John K. Chan
Jonathan S. Berek
Kathleen N. Moore
Masoud Azodi
Melissa Ann Geller
Mihaela C. Cristea
Noelle Gillette Cloven
Paul DiSilvestro
Romnee Clark
Ursula A. Matulonis
Yong Li
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.
Author
Alexander Olawaiye
Alice Chen
+18Â more
Amit M. Oza
Andrea Elisabeth Wahner Hendrickson
Cristina Martin-Lorente
Gini F. Fleming
Helen Mackay
Irene Brana
Jacklyn Ward
James Brenton
Johanne Ingrid Weberpals
Karen Chang
Katherine Karakasis
Lisa Wang
Michelle K. Wilson
Neesha C. Dhani
Stephanie Lheureux
Valerie Lydia Bowering
Vanessa Speers
Victor Rodriguez-Freixinos
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
Author
Andrea Elisabeth Wahner Hendrickson
Andres Forero-Torres
+18Â more
Antoinette R. Tan
Bruce Jeffrey Dezube
Carey K. Anders
Corrine Zarwan
Filipa Lynce
Georgia Anne-Lee McCann
Gerburg M. Wulf
Haroun Achour
John Kalil Erban
Lee Steven Schwartzberg
Melinda L. Telli
Monica M. Mita
Nathan Buerstatte
Patrick M Dillon
Sara M. Tolaney
Shaveta Vinayak
Sujata Arora
Yinghui Zhou
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref